Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 31

Sort by

Sort Order Select

Journal Articles

HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance

Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba, Beatrice Thier, Julia Kretz, Antje Sucker, Manuel Philip, Gennadiy Zelinskyy, Soldano Ferrone, Alexander Roesch, Susanne Horn, Eva Hadaschik, Dirk Schadendorf, Mirko Trilling, Ulf Dittmer, Klaus Griewank, Fang Zhao, Annette Paschen

Clin Cancer Res (2023) 29 (15): 2894–2907.

https://doi.org/10.1158/1078-0432.CCR-23-0099

Published: 01 August 2023

View article titled, HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance

Includes: Supplementary data

Journal Articles

Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Andrew W. Hahn, Ashley V. Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Jun Li, Xiaogang Wu, Aditya K. Mishra, Tuba N. Gide, Camelia Quek, Yan Zang, Christine N. Spencer, Alexander M. Menzies, Carrie R. Daniel, Courtney W. Hudgens, Theodore Nowicki, Lauren E. Haydu, M.A. Wadud Khan, Vancheswaran Gopalakrishnan, Elizabeth M. Burton, Jared Malke, Julie M. Simon, Chantale Bernatchez, Nagireddy Putluri, Scott E. Woodman, Y.N. Vashisht Gopal, Renato Guerrieri, Grant M. Fischer, Jian Wang, Khalida M. Wani, John F. Thompson, Jeffrey E. Lee, Patrick Hwu, Nadim Ajami, Jeffrey E. Gershenwald, Georgina V. Long, Richard A. Scolyer, Michael T. Tetzlaff, Alexander J. Lazar, Dirk Schadendorf, Jennifer A. Wargo, John M. Kirkwood, Ralph J. DeBerardinis, Han Liang, Andrew Futreal, Jianhua Zhang, James S. Wilmott, Weiyi Peng, Michael A. Davies, Greg M. Delgoffe, Yana G. Najjar, Jennifer L. McQuade

Clin Cancer Res (2023) 29 (1): 154–164.

https://doi.org/10.1158/1078-0432.CCR-22-2661

Published: 04 January 2023

View article titled, Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Includes: Supplementary data

Journal Articles

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

Clin Cancer Res (2021) 27 (16): 4500–4510.

https://doi.org/10.1158/1078-0432.CCR-20-3586

Published: 15 August 2021

View article titled, Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

Includes: Supplementary data

Journal Articles

Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

Tan-Trieu Nguyen, LeeAnn Ramsay, Mozhdeh Ahanfeshar-Adams, Mathieu Lajoie, Dirk Schadendorf, Tommy Alain, Ian R. Watson

Clin Cancer Res (2021) 27 (12): 3432–3442.

https://doi.org/10.1158/1078-0432.CCR-20-3365

Published: 15 June 2021

View article titled, Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

Includes: Supplementary data

Journal Articles

Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma

Ivelina Spassova, Selma Ugurel, Patrick Terheyden, Antje Sucker, Jessica C. Hassel, Cathrin Ritter, Linda Kubat, Daniel Habermann, Farnoush Farahpour, Mohammadkarim Saeedghalati, Lukas Peiffer, Rajiv Kumar, David Schrama, Daniel Hoffmann, Dirk Schadendorf, Jürgen C. Becker

Clin Cancer Res (2020) 26 (9): 2257–2267.

https://doi.org/10.1158/1078-0432.CCR-19-2244

Published: 01 May 2020

View article titled, Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma

Includes: Supplementary data

Journal Articles

Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma

Kaiji Fan, Cathrin Ritter, Paul Nghiem, Astrid Blom, Monique E. Verhaegen, Andrzej Dlugosz, Niels Ødum, Anders Woetmann, Richard W. Tothill, Rodney J. Hicks, Michael Sand, David Schrama, Dirk Schadendorf, Selma Ugurel, Jürgen C. Becker

Clin Cancer Res (2018) 24 (23): 5873–5882.

https://doi.org/10.1158/1078-0432.CCR-18-1184

Published: 03 December 2018

View article titled, Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma

Includes: Supplementary data

Journal Articles

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Clin Cancer Res (2018) 24 (21): 5347–5356.

https://doi.org/10.1158/1078-0432.CCR-18-1116

Published: 01 November 2018

View article titled, Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Includes: Supplementary data

Journal Articles

Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling

Klaus G. Griewank, Christian Koelsche, Johannes A.P. van de Nes, Daniel Schrimpf, Marco Gessi, Inga Möller, Antje Sucker, Richard A. Scolyer, Michael E. Buckland, Rajmohan Murali, Torsten Pietsch, Andreas von Deimling, Dirk Schadendorf

Clin Cancer Res (2018) 24 (18): 4494–4504.

https://doi.org/10.1158/1078-0432.CCR-18-0763

Published: 14 September 2018

View article titled, Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling

Includes: Supplementary data

Journal Articles

Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma

Vladimir Bezrookove, Mehdi Nosrati, James R. Miller, III, David De Semir, Altaf A. Dar, Elham Vosoughi, Edith Vaquero, Antje Sucker, Alexander J. Lazar, Jeffrey E. Gershenwald, Michael A. Davies, Dirk Schadendorf, Mohammed Kashani-Sabet

Clin Cancer Res (2018) 24 (17): 4119–4125.

https://doi.org/10.1158/1078-0432.CCR-18-0791

Published: 04 September 2018

View article titled, Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma

Includes: Supplementary data

Journal Articles

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Clin Cancer Res (2016) 22 (22): 5487–5496.

https://doi.org/10.1158/1078-0432.CCR-16-0127

Published: 14 November 2016

View article titled, Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Includes: Supplementary data

Journal Articles

Increases in Absolute Lymphocytes and Circulating CD4⁺ and CD8⁺ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Alexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, Michael A. Postow, Phillip Wong, Mariaelena Capone, Gabriele Madonna, Amir Khammari, Bastian Schilling, Antje Sucker, Dirk Schadendorf, Peter Martus, Brigitte Dreno, Paolo A. Ascierto, Jedd D. Wolchok, Graham Pawelec, Claus Garbe, Benjamin Weide

Clin Cancer Res (2016) 22 (19): 4848–4858.

https://doi.org/10.1158/1078-0432.CCR-16-0249

Published: 02 October 2016

View article titled, Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Includes: Supplementary data

Journal Articles

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Clin Cancer Res (2016) 22 (12): 2908–2918.

https://doi.org/10.1158/1078-0432.CCR-15-2412

Published: 14 June 2016

View article titled, Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Includes: Supplementary data

Journal Articles

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

Ademi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, Michelle Casey, Georgina V. Long, Dirk Schadendorf, Keith Flaherty, Richard Kefford, Axel Hauschild, Patrick Hwu, Patricia Haney, Anne O'Hagan, Jennifer Carver, Vicki Goodman, Jeffrey Legos, Anne-Marie Martin

Clin Cancer Res (2016) 22 (3): 567–574.

https://doi.org/10.1158/1078-0432.CCR-15-0321

Published: 31 January 2016

View article titled, Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

Includes: Supplementary data

Journal Articles

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

Christoffer Gebhardt, Alexandra Sevko, Huanhuan Jiang, Ramtin Lichtenberger, Maike Reith, Kathrin Tarnanidis, Tim Holland-Letz, Ludmila Umansky, Philipp Beckhove, Antje Sucker, Dirk Schadendorf, Jochen Utikal, Viktor Umansky

Clin Cancer Res (2015) 21 (24): 5453–5459.

https://doi.org/10.1158/1078-0432.CCR-15-0676

Published: 14 December 2015

View article titled, Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

Includes: Supplementary data

Journal Articles

Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression

Antje Sucker, Fang Zhao, Birgit Real, Christina Heeke, Nicola Bielefeld, Stefan Maβen, Susanne Horn, Iris Moll, Raffaela Maltaner, Peter A. Horn, Bastian Schilling, Francesco Sabbatino, Volker Lennerz, Matthias Kloor, Soldano Ferrone, Dirk Schadendorf, Christine S. Falk, Klaus Griewank, Annette Paschen

Clin Cancer Res (2014) 20 (24): 6593–6604.

https://doi.org/10.1158/1078-0432.CCR-14-0567

Published: 14 December 2014

View article titled, Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression

Includes: Supplementary data

Journal Articles

Circulating CD4⁺ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

Henning Zelba, Benjamin Weide, Alexander Martens, Evelyna Derhovanessian, Jithendra Kini Bailur, Christina Kyzirakos, Annette Pflugfelder, Thomas K. Eigentler, Anna Maria Di Giacomo, Michele Maio, Erik H.J.G. Aarntzen, Jolanda de Vries, Antje Sucker, Dirk Schadendorf, Petra Büttner, Claus Garbe, Graham Pawelec

Clin Cancer Res (2014) 20 (16): 4390–4399.

https://doi.org/10.1158/1078-0432.CCR-14-1015

Published: 13 August 2014

View article titled, Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

Includes: Supplementary data

Journal Articles

Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells

Benjamin Weide, Alexander Martens, Henning Zelba, Christina Stutz, Evelyna Derhovanessian, Anna Maria Di Giacomo, Michele Maio, Antje Sucker, Bastian Schilling, Dirk Schadendorf, Petra Büttner, Claus Garbe, Graham Pawelec

Clin Cancer Res (2014) 20 (6): 1601–1609.

https://doi.org/10.1158/1078-0432.CCR-13-2508

Published: 13 March 2014

View article titled, Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells

Includes: Supplementary data

Journal Articles

Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up

Selma Ugurel, Thomas Mentzel, Jochen Utikal, Peter Helmbold, Peter Mohr, Claudia Pföhler, Meinhard Schiller, Axel Hauschild, Rüdiger Hein, Eckhardt Kämpgen, Ivonne Kellner, Martin Leverkus, Jürgen C. Becker, Philip Ströbel, Dirk Schadendorf

Clin Cancer Res (2014) 20 (2): 499–510.

https://doi.org/10.1158/1078-0432.CCR-13-1411

Published: 16 January 2014

View article titled, Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up

Includes: Supplementary data

Journal Articles

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response

Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steuhl, Lisa Zimmer, Dirk Schadendorf

Clin Cancer Res (2013) 19 (22): 6331–6332.

https://doi.org/10.1158/1078-0432.CCR-13-2368

Published: 14 November 2013

View article titled, Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response

Journal Articles

Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas

Klaus G. Griewank, Henrike Westekemper, Rajmohan Murali, Monika Mach, Bastian Schilling, Thomas Wiesner, Tobias Schimming, Elisabeth Livingstone, Antje Sucker, Florian Grabellus, Claudia Metz, Daniela Süsskind, Uwe Hillen, Michael R. Speicher, Scott E. Woodman, Klaus-Peter Steuhl, Dirk Schadendorf

Clin Cancer Res (2013) 19 (12): 3143–3152.

https://doi.org/10.1158/1078-0432.CCR-13-0163

Published: 13 June 2013

View article titled, Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas

Includes: Supplementary data

NARROW

HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance

Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma

Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling

Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Increases in Absolute Lymphocytes and Circulating CD4⁺ and CD8⁺ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression

Circulating CD4⁺ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells

Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response

Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only